Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI)

Open access
Joseph, Adrien, Moriceau, Stéphanie, Sica, Valentina, Anagnostopoulos, Gerasimos, Pol, Jonathan, Martins, Isabelle, Lafarge, Antoine, Maiuri, Maria Chiara, Leboyer, Marion, Loftus, Josephine, Bellivier, Frank, Belzeaux, Raoul, Berna, Fabrice, Etain, Bruno, Capdevielle, Delphine, Courtet, Philippe, Dubertret, Caroline, Dubreucq, Julien, Thierry, D’. Amato, Fond, Guillaume, Gard, Sebastien, Llorca, Pierre-Michel, Mallet, Jasmina, Misdrahi, David, Olié, Emilie, Passerieux, Christine, Polosan, Mircea, Roux, Paul, Samalin, Ludovic, Schürhoff, Franck, Schwan, Raymond, the FACE-SZ and FACE-BD (FondaMental Academic Centers of Expertise, for Schizophrenia and for Bipolar Disorder) Groups, Magnan, Christophe, Oury, Franck, Bravo-San Pedro, José M., Kroemer, Guido · 2020 · Cell Death & Disease

Abstract

Acyl coenzyme A binding protein (ACBP), also known as diazepam binding inhibitor (DBI) is a multifunctional protein with an intracellular action (as ACBP), as well as with an extracellular role (as DBI). The plasma levels of soluble ACBP/DBI are elevated in human obesity and reduced in anorexia nervosa. Accumulating evidence indicates that genetic or antibody-mediated neutralization of ACBP/DBI has anorexigenic effects, thus inhibiting food intake and inducing lipo-catabolic reactions in mice. A number of anorexiants have been withdrawn from clinical development because of their side effects including an increase in depression and suicide. For this reason, we investigated the psychiatric impact of ACBP/DBI in mouse models and patient cohorts. Intravenously (i.v.) injected ACBP/DBI protein conserved its orexigenic function when the protein was mutated to abolish acyl coenzyme A binding, but lost its appetite-stimulatory effect in mice bearing a mutation in the γ2 subunit of the γ-aminobutyric acid (GABA) A receptor (GABA A R). ACBP/DBI neutralization by intraperitoneal (i.p.) injection of a specific mAb blunted excessive food intake in starved and leptin-deficient mice, but not in ghrelin-treated animals. Neither i.v. nor i.p. injected anti-ACBP/DBI antibody affected the behavior of mice in the dark–light box and open-field test. In contrast, ACBP/DBI increased immobility in the forced swim test, while anti-ACBP/DBI antibody counteracted this sign of depression. In patients diagnosed with therapy-resistant bipolar disorder or schizophrenia, ACBP/DBI similarly correlated with body mass index (BMI), not with the psychiatric diagnosis. Patients with high levels of ACBP/DBI were at risk of dyslipidemia and this effect was independent from BMI, as indicated by multivariate analysis. In summary, it appears that ACBP/DBI neutralization has no negative impact on mood and that human depression is not associated with alterations in ACBP/DBI concentrations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-020-2716-5

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Analysis of feeding behavior modulated by ACBP/DBI. a Cumulative food intake was measured after 60 min in WT mice injected with recombinant ACBP/DBI (recACBP/DBI) protein, its mutant forms Y29F or K33A (i.v., 0.5 mg/kg BW) or a vehicle control (a), in GABRA WT or GABRA knock-in (KI) mice upon recACBP/DBI i.v. injection (b), in WT mice after 24 h of starvation (Unfed) (c), in obese Ob/Ob or lean Ob/T mice (d), and in WT mice after Ghrelin injection (i.p., 10 µg/25 g BW) (e), all of them either alone or in combination with the i.p injection of an antibody against ACBP/DBI (anti-ACBP/DBI, i.p., 5 µg/g BW). Quantitative results are reported as box and whisker plots (mean, first and third quartiles, and maximum and minimum values). For statistical analyses, p values were calculated by two-way ANOVA (b) or one-way ANOVA with Tukey’s multiple comparisons test (a, c–e). Differences were considered statistically significant when p values *(p < 0.05), **(p < 0.01), ***(p < 0.001) and n.s. not significant (p > 0.05).
Fig. 1 Analysis of feeding behavior modulated by ACBP/DBI. a Cumulative food intake was measured after 60 min in WT mice injected with recombinant ACBP/DBI (recACBP/DBI) protein, its mutant forms Y29F or K33A (i.v., 0.5 mg/kg BW) or a vehicle control (a), in GABRA WT or GABRA knock-in (KI) mice upon recACBP/DBI i.v. injection (b), in WT mice after 24 h of starvation (Unfed) (c), in obese Ob/Ob or lean Ob/T mice (d), and in WT mice after Ghrelin injection (i.p., 10 µg/25 g BW) (e), all of them either alone or in combination with the i.p injection of an antibody against ACBP/DBI (anti-ACBP/DBI, i.p., 5 µg/g BW). Quantitative results are reported as box and whisker plots (mean, first and third quartiles, and maximum and minimum values). For statistical analyses, p values were calculated by two-way ANOVA (b) or one-way ANOVA with Tukey’s multiple comparisons test (a, c–e). Differences were considered statistically significant when p values *(p < 0.05), **(p < 0.01), ***(p < 0.001) and n.s. not significant (p > 0.05).CC BY · PubMed Central
Fig. 2 Dark–light test. a Examples of trajectories during the test by untreated (isotype) (upper panels) or anti-ACBP/DBI-treated mice (lower panels). b Percentage of time spent in the light (%), c number of accesses to light, d percentage of distance travelled in the light, and e latency to enter light in seconds were measured for 10 min. Quantitative results are reported as Box and whisker plots (mean, first and third quartiles, and maximum and minimum values) (n = 17). Symbols indicate statistical (Student’s t test) comparisons with isotype control (n.s not significant).
Fig. 2 Dark–light test. a Examples of trajectories during the test by untreated (isotype) (upper panels) or anti-ACBP/DBI-treated mice (lower panels). b Percentage of time spent in the light (%), c number of accesses to light, d percentage of distance travelled in the light, and e latency to enter light in seconds were measured for 10 min. Quantitative results are reported as Box and whisker plots (mean, first and third quartiles, and maximum and minimum values) (n = 17). Symbols indicate statistical (Student’s t test) comparisons with isotype control (n.s not significant).CC BY · PubMed Central
Fig. 3 Open-field test. a Examples of trajectories during the test by untreated (isotype) (upper panels) or anti-ACBP/DBI-treated mice (lower panels). b Total distance, c percentage of time spent in center (%), d speed, and e percentage of distance spent in center were measured during 30 min. Quantitative results are reported as Box and whisker plots (mean, first and third quartiles, and maximum and minimum values) (n = 8). Symbols indicate statistical (Student’s t test) comparisons with isotype control (n.s not significant and *p < 0.05).
Fig. 3 Open-field test. a Examples of trajectories during the test by untreated (isotype) (upper panels) or anti-ACBP/DBI-treated mice (lower panels). b Total distance, c percentage of time spent in center (%), d speed, and e percentage of distance spent in center were measured during 30 min. Quantitative results are reported as Box and whisker plots (mean, first and third quartiles, and maximum and minimum values) (n = 8). Symbols indicate statistical (Student’s t test) comparisons with isotype control (n.s not significant and *p < 0.05).CC BY · PubMed Central
Fig. 4 Immobility time in the forced swim test. Time spent immobile in seconds after anti-ACBP/DBI (n = 18) (b) or recACBP/DBI (n = 10) (c) treatments were measured for 5 min. Quantitative results are reported as Box and whisker plots (mean, first and third quartiles, and maximum and minimum values). Symbols indicate statistical (Student’s t test) comparisons with controls (*p < 0.05 and ***p < 0.001).
Fig. 4 Immobility time in the forced swim test. Time spent immobile in seconds after anti-ACBP/DBI (n = 18) (b) or recACBP/DBI (n = 10) (c) treatments were measured for 5 min. Quantitative results are reported as Box and whisker plots (mean, first and third quartiles, and maximum and minimum values). Symbols indicate statistical (Student’s t test) comparisons with controls (*p < 0.05 and ***p < 0.001).CC BY · PubMed Central
Fig. 5 No impact of pychiatric disease or weight evolution on the correlation between ACBP/DBI plasma concentration and body mass index. Scatter plot with regression line between ACBP/DBI (ng/mL) and body mass index (kg/m2) in bipolar and schizophrenic patients (a) and patients who lose weight (≥5%), gain weight (≥5%), or remain stable (variations < 5%) (b). Pearson’s correlation coefficient (R) and their p value are shown on top of each panel.
Fig. 5 No impact of pychiatric disease or weight evolution on the correlation between ACBP/DBI plasma concentration and body mass index. Scatter plot with regression line between ACBP/DBI (ng/mL) and body mass index (kg/m2) in bipolar and schizophrenic patients (a) and patients who lose weight (≥5%), gain weight (≥5%), or remain stable (variations < 5%) (b). Pearson’s correlation coefficient (R) and their p value are shown on top of each panel.CC BY · PubMed Central
Fig. 6 Impact of metabolic syndrome on ACBP/DBI levels. No impact of pychiatric disease or weight evolution on the correlation between ACBP/DBI plasma concentration and body mass index. Scatter plot with regression line between ACBP/DBI (ng/mL) and body mass index (kg/m2) in patients with or without metabolic syndrome. Pearson’s correlation coefficient (R) and their p value are shown on top of each panel. Forest plots representing odds ratios for the association between ACBP/DBI (per 1ng/mL increase) and obesity, abdominal obesity, dyslipidemia, hypertension, type 2 diabetes, and metabolic syndrome in univariate analysis (b) and after adjustment for body mass index (c).
Fig. 6 Impact of metabolic syndrome on ACBP/DBI levels. No impact of pychiatric disease or weight evolution on the correlation between ACBP/DBI plasma concentration and body mass index. Scatter plot with regression line between ACBP/DBI (ng/mL) and body mass index (kg/m2) in patients with or without metabolic syndrome. Pearson’s correlation coefficient (R) and their p value are shown on top of each panel. Forest plots representing odds ratios for the association between ACBP/DBI (per 1ng/mL increase) and obesity, abdominal obesity, dyslipidemia, hypertension, type 2 diabetes, and metabolic syndrome in univariate analysis (b) and after adjustment for body mass index (c).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 44

Metadata

Authors
Joseph, A., Moriceau, S., Sica, V., Anagnostopoulos, G., Pol, J., Martins, I., Lafarge, A., Maiuri, M. C., Leboyer, M., Loftus, J., Bellivier, F., Belzeaux, R., Berna, F., Etain, B., Capdevielle, D., Courtet, P., Dubertret, C., Dubreucq, J., Thierry, D. A., Fond, G., Gard, S., Llorca, P.-M., Mallet, J., Misdrahi, D., Olié, E., Passerieux, C., Polosan, M., Roux, P., Samalin, L., Schürhoff, F., Schwan, R., the FACE-SZ and FACE-BD (FondaMental Academic Centers of Expertise, F. S. A. F. B. D. G., Magnan, C., Oury, F., Bravo-San Pedro, J. M., & Kroemer, G.
Affiliations
  • Inserm (FR)
  • Hôpital Necker-Enfants Malades (FR)
  • Fondation FondaMental (FR)
  • Aix-Marseille Université (FR)
  • Université Clermont Auvergne (FR)
  • Karolinska University Hospital (SE)
Corresponding author
Kroemer, Guido
Venue
Cell Death & Disease
Published
2020-07-06
Volume
11
Issue
7
Pages
502-502
ISSN
2041-4889 (ISSN-L)
OpenAlex
W3038745725
Cited by
44
References
46
Citations by year
2026: 4 · 2025: 14 · 2024: 9 · 2023: 5 · 2022: 5 · 2021: 6 · 2020: 1
FWCI
2.18
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
Funders
  • Association pour la Recherche sur le Cancer (ANR-18-IDEX-0001)
  • Seerave Foundation
  • E-Rare
  • Fondation FondaMental
  • European Commission (HORIZON2020)
  • Agence Nationale de la Recherche (ANR-17-CE14-0030, UMS3655, ANR-10-COHO-0010, ANR18, ANR-19-CE14-0004, E-Rare-2, ANR-16-RHUS-0008, ANR-18-IDEX-0001)
  • Fondation Leducq
  • Institut National de la Santé et de la Recherche Médicale (ANR-18-IDEX-0001)
  • Fondation pour la Recherche Médicale
  • Ligue Contre le Cancer
  • Centre National de la Recherche Scientifique (#ANR-18-IDEX-0001, UMS3655)
  • Institut Universitaire de France (ANR-18-IDEX-0001)
  • Institut National Du Cancer (#ANR-18-IDEX-0001)
  • Institut Gustave-Roussy (UMS3655)
  • European Research Area Network on Cardiovascular Diseases
  • High-end Foreign Experts Recruitment Plan of China (GDW20171100085)
  • Labex Immuno-Oncology ((ANR-18-IDEX-0001))
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
diazepam binding inhibitor, appetite regulation, dietary intake, obesity, anorexia nervosa, depression, forced swim test, GABAA receptor, leptin, ghrelin, dyslipidemia, body mass index, bipolar disorder, schizophrenia
MeSH terms
Animals, Appetite, Behavior, Animal, Mental Disorders, Darkness, Feeding Behavior, Immobilization, Male, Mice, Inbred C57BL, Receptors, GABA-A, Swimming, Body Mass Index, Metabolic Syndrome, Diazepam Binding Inhibitor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI). https://app.cochat.ai/papers/10.1038/s41419-020-2716-5
The paper
Joseph, A., Moriceau, S., Sica, V., Anagnostopoulos, G., Pol, J., Martins, I., Lafarge, A., Maiuri, M. C., Leboyer, M., Loftus, J., Bellivier, F., Belzeaux, R., Berna, F., Etain, B., Capdevielle, D., Courtet, P., Dubertret, C., Dubreucq, J., Thierry, D. A., . . . Kroemer, G. (2020). Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI). Cell Death & Disease. https://doi.org/10.1038/s41419-020-2716-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.